SHERIDAN, WYOMING - April 13, 2026 - The European Medicines Agency (EMA) has deployed its first social media campaign using partnered content creators, targeting the surge of misinformation surrounding GLP-1 receptor agonists. The #HealthNotHype initiative enlists healthcare professionals and nutrition experts from seven EU Member States to deliver evidence-based messaging on Instagram, where GLP-1 conversations have reached high volumes and often circulate without medical oversight. The campaign addresses a direct regulatory concern: soaring public interest in these medicines has generated parallel risks, including counterfeit product sales, unsupervised use, and misrepresentation of clinical outcomes. Running for approximately one month from launch, the initiative marks a strategic shift for EMA toward direct-to-public digital engagement.

SHERIDAN, WYOMING - April 12, 2026 - Packaging and processing equipment buyers across Asia-Pacific face a concentrated sourcing window in November 2026, when interpack China 2026 convenes more than 950 global leading enterprises on a single platform in Shanghai, giving procurement and supply chain teams one of the region's largest consolidated views of packaging technology available this year.

Event scope and organizer

interpack China 2026 is organized jointly by Messe Düsseldorf (Shanghai) Co., Ltd. and Adsale Exhibition Services Ltd., combining the global brand authority of the Düsseldorf-based interpack franchise with Adsale's deep distribution network across Greater China and Hong Kong. Messe Düsseldorf (Shanghai) operates from Units 2902-2904A, Sinar Mas Plaza, 501 Dongdaming Road, Hongkou District, Shanghai, positioning the event squarely within China's primary commercial hub for international trade exhibition activity.

SHERIDAN, WYOMING - April 12, 2026 - The International Air Transport Association (IATA) has publicly rejected AENA's bid for a 16% airport charges increase in Spain, calling out AENA Chairman and CEO Maurici Lucena for claiming that airlines seeking lower charges were "compromising safety and security." IATA Director General Willie Walsh dismissed the claim as scaremongering with no factual basis, pointing instead to AENA's EUR 1.32 billion in excess returns over two regulatory periods and a 2024 net profit margin of 36.4%-against an average European airline net margin of 3.5%. The dispute puts airport regulation, consumer airfare affordability, and Spain's aviation competitiveness directly in the crosshairs of a high-stakes policy confrontation.

SHERIDAN, WYOMING - April 12, 2026 - The U.S. Senate passed legislation reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which had lapsed on September 30, 2025, cutting off competitive grant access for early-stage medtech companies. AdvaMed, the Medtech Association, publicly supported the Senate vote and called on the House of Representatives to act swiftly on passage. The programs channel competitive grants through 11 federal agencies - including the National Institutes of Health, the National Science Foundation, and the Department of Defense - directly to small medtech businesses at the most capital-constrained stages of product development. Restoring authorization removes a period of funding uncertainty that had stalled R&D planning across hundreds of early-stage medical device companies.

SHERIDAN, WYOMING - April 12, 2026 - Early-stage medtech companies that lost access to federal competitive grant funding when SBIR and STTR program authorization lapsed on April 12, 2026, now face a clearer path to restored capital after both chambers of Congress advanced reauthorization legislation. The Senate passed the measure first, followed by House passage of S. 3971, the Small Business Innovation and Economic Security Act, on April 12, 2026, bringing the programs within reach of full restoration pending presidential signature.

SHERIDAN, WYOMING - April 12, 2026 - ABK Biomedical has completed enrollment of all 120 patients in ROUTE90, its pivotal U.S. FDA Investigational Device Exemption study evaluating Eye90 microspheres® for unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The milestone positions the Halifax-based medical device company to finalize one-year patient follow-up, then submit a Premarket Approval (PMA) application to the FDA. Eye90 microspheres hold FDA Breakthrough Device Designation, signaling regulatory recognition of the device's potential to address an unmet clinical need in liver cancer care.

SHERIDAN, WYOMING - April 10, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.

Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration

Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.

SHERIDAN, WYOMING - April 10, 2026 - Industrial facility operators across Germany and the broader DACH region face tightening inspection and compliance requirements in 2026, as the TÜV Association's annual Plant Safety Report (Anlagensicherheitsreport) documents the current state of accident prevention, technical inspections, and regulatory oversight for hazardous installations. The report forms a critical reference point for plant managers, insurers, and regulators assessing risk exposure across chemical, energy, and heavy manufacturing sectors.

SHERIDAN, WYOMING - April 10, 2026 - AGC Biologics has tied an expansion of microbial manufacturing capacity at its Heidelberg facility to a limited-time commercial offer for late-phase and commercial drug developers. The company said it is offering VIP priority slots and set pricing for 10,000 L GMP production, positioning the package as a way to secure supply and reduce exposure to delays. For biopharma companies moving toward launch or scale-up, the development matters because capacity access, price visibility and site selection can materially affect supply planning, regulatory execution and commercial readiness.

SHERIDAN, WYOMING - April 09, 2026 - Industrial procurement and technology roadmaps face a concrete inflection point as HANNOVER MESSE 2026 positions AI-driven factory automation, autonomous robotics, and sustainable energy sourcing as the defining operational priorities for the year, with live deployments on display across the Hannover exhibition grounds from April 20 to 24.